<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38757870</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Risks of alopecia areata in long COVID: Binational population-based cohort studies from South Korea and Japan.</ArticleTitle><Pagination><StartPage>e29668</StartPage><MedlinePgn>e29668</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29668</ELocationID><Abstract><AbstractText>Previous studies have proposed alopecia areata (AA) as a potential outcome of COVID-19 infection among autoimmune diseases, yet the findings might be inconclusive and difficult to generalize due to limited sample sizes and evidence levels. Thus, we aimed to investigate in detail the long-term risk of AA following SARS-CoV-2 infection based on large, binational, general population-based cohort studies. Our study investigated the long-term AA risk after SARS-CoV-2 infection by analyzing bi-national, claim-based cohorts in South Korea and Japan: a Korean nationwide cohort (K-COV-N cohort; discovery cohort; total n&#x2009;=&#x2009;10&#x2009;027&#x2009;506) and a Japanese claims-based cohort (JMDC cohort; validation cohort; total n&#x2009;=&#x2009;12&#x2009;218&#x2009;680). AA was identified based on the international classification of diseases 10th revision code (L63) requiring at least three claims within 1 year. After exposure-driven propensity score matching, SARS-CoV-2 infection was associated with an increased risk of incident AA (aHR, 1.66; 95% CI, 1.38-1.99). This increased risk was observed and persisted for up to 6 months. A similar pattern was observed in the validation cohort. As modifiable factors, severe COVID-19 increased the risk of AA, whereas receiving two or more doses of the COVID-19 vaccine before infection decreased the risk of AA. Through a bi-national cohort study in South Korea and Japan, SARS-CoV-2 infection was associated with an elevated risk for incident AA in the aspect of long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kyung</LastName><ForeName>Seoyeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Yejun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Minji</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jiseung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Division of Sleep Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hayeon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yon</LastName><ForeName>Dong Keon</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0003-1628-9948</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RS-2023-00248157</GrantID><Agency>National Research Foundation of Korea (NRF)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000506" MajorTopicYN="Y">Alopecia Areata</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2 infection</Keyword><Keyword MajorTopicYN="N">alopecia areata</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">vaccines/vaccine strains</Keyword><Keyword MajorTopicYN="N">virus classification</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>8</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38757870</ArticleId><ArticleId IdType="doi">10.1002/jmv.29668</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus&#x2010;2 (SARS&#x2010;CoV&#x2010;2): a global pandemic and treatment strategies. Int J Antimicro Ag. 2020;56(2):106054.</Citation></Reference><Reference><Citation>Shin YH, Shin JI, Moon SY, et al. Autoimmune inflammatory rheumatic diseases and COVID&#x2010;19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021;3(10):e698&#x2010;e706.</Citation></Reference><Reference><Citation>Christensen RE, Jafferany M. Association between alopecia areata and COVID&#x2010;19: a systematic review. JAAD Int. 2022;7:57&#x2010;61.</Citation></Reference><Reference><Citation>Nguyen B, Tosti A. Alopecia in patients with COVID&#x2010;19: a systematic review and meta&#x2010;analysis. JAAD Int. 2022;7:67&#x2010;77.</Citation></Reference><Reference><Citation>Kim JS, Lee GJ, Jeong CY, et al. Risk of alopecia areata after COVID&#x2010;19. JAMA Dermatol. 2024;160(2):232&#x2010;235.</Citation></Reference><Reference><Citation>Kim MS, Lee H, Lee SW, et al. Long&#x2010;term autoimmune inflammatory rheumatic outcomes of COVID&#x2010;19: a binational cohort study. Ann Intern Med. 2024;177:291&#x2010;302.</Citation></Reference><Reference><Citation>Kang J, Lee M, Park M, et al. Slow gut transit increases the risk of Alzheimer's disease: an integrated study of the bi&#x2010;national cohort in South Korea and Japan and Alzheimer's disease model mice. J Adv Res. Published online December 13, 2023. doi:10.1016/j.jare.2023.12.010</Citation></Reference><Reference><Citation>Kyung S, Woo S, Kim M, et al. Global burden of vaccine&#x2010;associated alopecia, 1979&#x2013;2023: a comprehensive analysis of the international pharmacovigilance database. Br J Dermatol. 2024;190:764&#x2010;767.</Citation></Reference><Reference><Citation>Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post&#x2010;COVID&#x2010;19 manifestation. J Med Virol. 2022;94(4):1391&#x2010;1401.</Citation></Reference><Reference><Citation>Lavian J, Li S, Lee E, et al. Validation of case identification for alopecia areata using international classification of diseases coding. Int J Trichol. 2020;12(5):234&#x2010;237.</Citation></Reference><Reference><Citation>Schneeweiss MC, Mostaghimi A, Chiuve S, et al. Validation of alopecia coding in US claims data among women of childbearing age. Pharmacoepidemiol Drug Saf. 2024;33(4):e5782.</Citation></Reference><Reference><Citation>Lee SW, Kim SY, Moon SY, et al. Estimating COVID&#x2010;19 infection and severity risks in patients with chronic rhinosinusitis: a Korean nationwide cohort study. J Allergy Clin Immunol Pract. 2021;9(6):2262&#x2010;2271.</Citation></Reference><Reference><Citation>Kang J, Kim HJ, Kim T, et al. Prenatal opioid exposure and subsequent risk of neuropsychiatric disorders in children: nationwide birth cohort study in South Korea. BMJ. 2024;385:e077664.</Citation></Reference><Reference><Citation>Rahmati M, Yon DK, Lee SW, et al. New&#x2010;onset neurodegenerative diseases as long&#x2010;term sequelae of SARS&#x2010;CoV&#x2010;2 infection: a systematic review and meta&#x2010;analysis. J Med Virol. 2023;95(7):e28909.</Citation></Reference><Reference><Citation>Hadanny A, Zilberman&#x2010;Itskovich S, Catalogna M, et al. Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow&#x2010;up of a randomized controlled trial. Sci Rep. 2024;14(1):3604.</Citation></Reference><Reference><Citation>Finnigan LEM, Cassar MP, Koziel MJ, et al. Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue&#x2010;predominant long COVID: a single&#x2010;centre, double&#x2010;blind, randomised controlled phase 2a pilot study. EClinicalMedicine. 2023;59:101946.</Citation></Reference><Reference><Citation>McIntyre RS, Phan L, Kwan ATH, et al. Vortioxetine for the treatment of post&#x2010;COVID&#x2010;19 condition: a randomized controlled trial. Brain. 2024;147(3):849&#x2010;857.</Citation></Reference><Reference><Citation>Oh J, Lee M, Kim M, et al. Incident allergic diseases in post&#x2010;COVID&#x2010;19 condition: multinational cohort studies from South Korea, Japan and the UK. Nat Commun 2024;15(1):2830.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>